Dear Sir, IA-2 m R N A is expressed in both human pancreatic islets and brain [1] . It encodes a 979 amino acid protein that is a major autoantigen in insulin-dependent diabetes mellitus (IDDM) [2, 3]. Up to 70 % of IDDM patients have antibodies to . In clinically non-diabetic subjects, the appearance of autoantibodies to IA-2 is highly predictive in identifying individuals at high risk of subsequently developing clinical disease [5].
NOD Human
I II I Fig.1 . Radioimmunoprecipitation of mouse recombinant IA-2. NOD/Lt mouse and human sera were incubated with mouse recombinant IA-2 expressed in a rabbit reticulocyte system. The precipitates were separated on an 8 % SDS-PAGE gel.
Bands with a molecular mass of approximately 106 kDa were precipitated by mouse monoclonal anti-IA-2 antibody-161 and two human diabetic sera that were shown to react strongly with human IA-2 recombinant protein in a previous study used in therapeutic trials [6] . In humans, autoantibodies to islet cells [9] , insulin [10] , and glutamic acid deearboxylase [11] are particularly important predictive markers for the development of IDDM. Some, but not all, of these autoantibodies have also been found in NOD mice and BB rats [12] [13] [14] . Their role in the pathogenesis of IDDM, however, remains unclear. The failure reported here to find autoantibodies to recombinant mouse IA-2, by a very sensitive test, points to still another difference in the autoimmune responses of animals and humans with IDDM. This finding, however, does not detract from the usefulness of NOD mice and BB rats in studies involving autoimmune pathogenesis and therapy. 
Mortality of childhood-onset IDDM patients in Estonia
Dear Sir, Insulin-dependent diabetes mellitus (IDDM) leads to excess risk of mortality in developed countries even today [1] . Virtually no data are available on the mortality of IDDM patients in eastern Europe apart from a report from former East Germany on insulin-treated patients [2] . We report the mortality among childhood-onset IDDM patients from Estonia which until 1991 was a constituent republic of the former Soviet Union. Patients were taken from the Estonian population-based childhood-onset IDDM registry which since 1980 has collected information on newly diagnosed cases aged 0--14 years [3] . Between 1 January 1980 and 31 December 1989 340 children were diagnosed with IDDM in Estonia. Registration of cases during 1980-1989 was estimated to be at least 95 % complete using the capture-mark-recapture approach.
The survival status of this cohort was determined as of 1 January 1992. Attending physicians were asked to note the last date when the patient had visited the office or had been hospitalized. Additional information was obtained from currency exchange lists. Currency exchange took place in Estonia in June 1992 and those on the list had to be alive on 1 January 1992. In a minority of cases untraceable by these methods, telephone interviews were conducted and/or the cases traced by mail. Follow-up information was available on 339 cases (99.7 %). The only untraceable case was censored i week after diagnosis as the possibility of death of the patient was excluded. Seven subjects had emigrated and were censored at Corresponding author." T. Podar, MD, Hospital of Endocrinology, Pikk 64, EE-2400 Tartu, Estonia the date last known to be alive. Since information on death certificates is known to be imprecise [4], the cause of death in each case was determined by careful review of hospital records and interviews with physicians and relatives by one of the investigators (T. R). Background data on the mortality of the population of Estonia were obtained from the Department of Epidemiology and Biostatistics, Institute of Experimental and Clinical Medicine. Life-table analysis was used for the assessment of the survival of the cohort. Standardized mortality ratios (SMR) were computed using the computer package PersonYears [5] . 95 % confidence intervals (CI) of SMRs were calculated assuming the Poisson distribution.
The mean duration of follow-up was 6.1 years (range 0. 12). The oldest possible attained age was 26 years. During the follow-up 10 (2.95 %) individuals died, seven male and three female. The crude mortality rate among the cohort was 425 per 100000 person-years. The 10-year cumulative mortality of the cohort was high at 6.1%. The overall SMR (all causes) for the age group 0-29 years was 5.0l (95 % CI 2.41-9.22) ( Table 1) . SMRs for males and females were similar and nonEstonians tended to have a somewhat higher SMR than Estonians (8.85 (95% CI 1.82-25.84) vs 3.50 (95 % CI 1.40-7.21), respectively).
Deaths were most often due to diabetic ketoacidosis, the main killer of the pre-insulin era, which accounted for 50 % of deaths, four in males (57 %) and one in females (33 %). One male died from diabetic ketoacidosis at the onset of IDDM. One female was found dead in bed which could have been related to an acute diabetic complication but the possibility of suicide could not be excluded. One male and one female died because of cancer and two males in motorvehicle accidents. Careful investigation of the circumstances of the accidents revealed that in neither case was diabetes the cause. No deaths were due to chronic complications of IDDM or cardiovascular disease.
Despite the small size of the cohort and small number of deaths, these data should give an adequate estimate of the
